Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP

@article{Pu2008EffectsOC,
  title={Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP},
  author={Q. Pu and P. Brassard and D. Javeshghani and M. Iglarz and R. Webb and F. Amiri and E. Schiffrin},
  journal={Journal of Hypertension},
  year={2008},
  volume={26},
  pages={322–333}
}
Background The association of an angiotensin-converting enzyme inhibitor (ACEI) with a neutral endopeptidase inhibitor (NEPI) has potent blood pressure (BP) lowering action, but is associated with side-effects. We evaluated the effects of combining an angiotensin II type 1 (AT1) receptor blocker (ARB, valsartan) and a NEPI (CGS 25354) in comparison with a dual ACEI/NEPI (CGS 30440) in stroke-prone spontaneously hypertensive rats (SHRSP). Methods and results Ten-week-old SHRSP were treated with… Expand
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
From ARB to ARNI in Cardiovascular Control
...
1
2
3
4
...

References

SHOWING 1-10 OF 43 REFERENCES
AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats
  • T. Walther, W. Siems, +5 authors C. Tschöpe
  • Chemistry, Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2002
...
1
2
3
4
5
...